ArticleInternational journal of molecular sciences2016
HER2 Analysis in Sporadic Thyroid Cancer of Follicular Cell Origin.
Article in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 22 citations in OpenAlex.
- Advances in Optical and Fluorescence Imaging for Surgical Management of Thyroid Cancer.Cancers · 2026Review
- Prognostic and Predictive Roles of HER2 Status in Non-Breast and Non-Gastroesophageal Carcinomas.Cancers · 2024Review
- Links between Breast and Thyroid Cancer: Hormones, Genetic Susceptibility and Medical Interventions.Cancers · 2022Review
- Review
- ERBB2 as a prognostic biomarker correlates with immune infiltrates in papillary thyroid cancer.Frontiers in genetics · 2022Article
- Next-Generation Molecular Imaging of Thyroid Cancer.Cancers · 2021Review
- Novel Therapeutics in Radioactive Iodine-Resistant Thyroid Cancer.Frontiers in endocrinology · 2021Review
- HER2 Heterogeneity in Personalized Therapy of Gastro-Oesophageal Malignancies: An Overview by Different Methodologies.Journal of personalized medicine · 2020Review
- Distribution and Prognostic Significance of Estrogen ReceptorJournal of thyroid research · 2020Article
- HER2-targeted multimodal imaging of anaplastic thyroid cancer.American journal of cancer research · 2019Article
- Novel targeted therapies and immunotherapy for advanced thyroid cancers.Molecular cancer · 2018Review
- Current Knowledge in Thyroid Cancer-From Bench to Bedside.International journal of molecular sciences · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Epidermal Growth Factor Receoptor (EGFR) family member human epidermal growth factor receptor 2 (HER2) is overexpressed in many human epithelial malignancies, representing a molecular target for specific anti-neoplastic drugs. Few data are available on HER2 status in differentiated thyroid cancer (DTC). The present study was aimed to investigate HER2 status in sporadic cancers of follicular cell origin to better clarify the role of this receptor in the stratification of thyroid cancer. By immunohistochemistry and fluorescence in-situ hybridization, HER2 expression was investigated in formalin-fixed paraffin-embedded surgical specimens from 90 DTC patients, 45 follicular (FTC) and 45 papillary (PTC) histotypes. No HER2 immunostaining was recorded in background thyroid tissue. By contrast, overall HER2 overexpression was found in 20/45 (44%) FTC and 8/45 (18%) PTC, with a significant difference between the two histotypes (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.